Skip to content
FrontierPicks

Dossier · OTLY · Dormant

OTLY · Oatly Group AB · Stock research

Last analysed ·

Current thesis

The 2026-07-22 guidance doubling (FY constant-currency growth 8–10% from 3–5%) is now a month old with no follow-on news; RSI(14) reset from 71.0 on 2026-08-07 to 43.7 on 2026-08-21 while price held, leaving a $13.03–$13.15 shelf. Nothing company-scheduled before the ~2026-10-28 Q3 print, against $517.8M borrowings, $44.6M cash and a $462.7M market cap.

Kill line

A weekly close below $13.00 removes the August 2026 shelf (closes of $13.035 on 2026-08-11 and $13.150 on 2026-08-12), the only floor the post-guidance advance built; secondarily, a Q3 2026 print (~2026-10-28, est.) walking FY constant-currency growth back toward 3–5% or narrowing adjusted EBITDA below $25M.

Pick status

Open commitment scored if the kill line above fires How this is scored →

Latest analysis and events for OTLY —

As of 22 August 2026, the latest FrontierPicks analysis for Oatly Group AB (OTLY): The 2026-07-22 guidance doubling (FY constant-currency growth 8–10% from 3–5%) is now a month old with no follow-on news; RSI(14) reset from 71.0 on 2026-08-07 to 43.7 on 2026-08-21 while price held, leaving a $13.03–$13.15 shelf. Nothing company-scheduled before the ~2026-10-28 Q3 print, against $517.8M borrowings, $44.6M cash and a $462.7M market cap.

Kill line: A weekly close below $13.00 removes the August 2026 shelf (closes of $13.035 on 2026-08-11 and $13.150 on 2026-08-12), the only floor the post-guidance advance built; secondarily, a Q3 2026 print (~2026-10-28, est.) walking FY constant-currency growth back toward 3–5% or narrowing adjusted EBITDA below $25M.

Current Thesis

The leg on offer is unchanged in substance and older in time: an operating inflection printed on 2026-07-22 — Q2 net revenue $240.1M (+15.2% reported, +12.7% constant currency) against a $218.961M consensus, adjusted EBITDA crossing positive at +$0.4M, and FY2026 constant-currency growth guidance doubled to 8–10% from 3–5% — sitting on top of $517.8M of total borrowings against $44.6M of cash at 2026-06-30.

What has changed since the last write-up is the market's condition, not the fundamentals. On the 2026-08-07 close of $13.72, RSI(14) read 71.0. On the 2026-08-21 close of $14.50, RSI(14) reads 43.7. In between, the stock closed at $13.035 on 2026-08-11 and $13.150 on 2026-08-12 (per contemporaneous quote data), then recovered. The overbought reading was worked off through time and a shallow dip rather than a full retracement — an inference from the price path, not a company event. No press release, no SEC filing and no dated sell-side action surfaced between 2026-07-24 and 2026-08-21; an EDGAR search returned no August 2026 Form 6-K.

The narrative is maturing. The story is fully disclosed and still working — the shares are up 42.9% over three months — but the flow that carried it has moderated: last company headline 2026-07-24, no new information for roughly four weeks, and no scheduled company event before the estimated late-October Q3 print. It is no longer accelerating because the headline stream stopped; it is not saturated because the price never reached the $18.54 52-week high (-21.8% from it at $14.50) and sell-side participation stayed thin (JPMorgan and Morgan Stanley at hold in late July 2026).

Bullish and bearish views on Oatly Group AB

The model's bull view on Oatly Group AB (OTLY), in brief: FY2026 constant-currency revenue growth guidance raised to 8–10% from 3–5% on 2026-07-22 — the growth assumption doubled inside one quarter. The bear view: Debt exceeds the equity. $517.8M of total borrowings against $44.6M of cash at 2026-06-30, versus a market capitalisation of $462.73M on 31.91M shares outstanding at the 2026-08-21 close (stockanalysis.com, checked 2026-08-22). The 9.25% Convertible Senior PIK Notes due… Both cases follow in full.

Bull Case

  • FY2026 constant-currency revenue growth guidance raised to 8–10% from 3–5% on 2026-07-22 — the growth assumption doubled inside one quarter.
  • Q2 2026 revenue $240.095M vs $218.961M consensus; EPS -$0.99 vs -$1.06 consensus (Benzinga, 2026-07-22). Six-month revenue $468.4M.
  • Adjusted EBITDA turned positive at +$0.4M (from -$3.6M in Q2 2025); gross margin 33.9%, +140bps; net loss narrowed to $31.3M from $55.9M.
  • Regional breadth in the quarter: Europe & International +21.0% reported (+18.0% cc); Greater China +11.6% (+5.6% cc); North America +5.9% with a second consecutive quarter of positive volume growth.
  • Low capital intensity relative to the growth rate: H1 2026 capex $10.7M.
  • Barclays kept Overweight and raised its target to $14 on 2026-07-23, two days after cutting it to $12. Aggregator target sets disagree materially: WallStreetZen shows a one-analyst 12-month target of $14.00, while a six-analyst set tracked in August 2026 averages $17.25 with a $24.00 high and a $12.00 low.
  • The August drawdown to the $13.03–$13.15 area held and the 2026-08-21 close of $14.50 is above the 2026-08-07 close of $13.72 — the guidance-raise gap has not been filled back.

Bear Case

  • Debt exceeds the equity. $517.8M of total borrowings against $44.6M of cash at 2026-06-30, versus a market capitalisation of $462.73M on 31.91M shares outstanding at the 2026-08-21 close (stockanalysis.com, checked 2026-08-22). The 9.25% Convertible Senior PIK Notes due 2028-09-14 accrete rather than pay cash, so principal compounds absent repurchase.
  • The dollar guide moved from $866.725M–$883.555M to $908.799M–$925.629M against a $917.899M consensus (Benzinga, 2026-07-22) — the midpoint met the Street rather than clearing it.
  • Reported growth of 15.2% versus 12.7% constant currency is roughly 250bps of currency help in a company that reports in USD while its fastest-growing region is European.
  • Management pointed to the low end of the $25–35M FY adjusted-EBITDA range on the 2026-07-22 call.
  • Still loss-making at -$31.3M in the quarter, with one quarter of positive adjusted EBITDA as the entire track record of the inflection.
  • Four weeks without a company datapoint, and roughly nine weeks until the next one. A re-rating that depends on a single guide has nothing scheduled to refresh it.

Setup & Price Structure

  • Reference close 2026-08-21: $14.50. 52-week high $18.54, so -21.8% below it. Three-month price change +42.9%. RSI(14) 43.7.
  • The only structure the post-guidance advance has built is the August consolidation shelf marked by the $13.035 close on 2026-08-11 and the $13.150 close on 2026-08-12. Below that, the next reference is the pre-2026-07-22 range that the print gapped out of.
  • Crowding/positioning observables, stated as observables. RSI(14) fell from 71.0 (2026-08-07) to 43.7 (2026-08-21) with price higher — the momentum-screen hook that produced the 2026-07-24 Benzinga RSI piece has cooled. There is no new 52-week high to attract breakout participation. No earnings date falls inside 30 days. No August 2026 company filing surfaced on EDGAR, so no issuance-into-strength or insider transaction is on the record for the period; that is an absence of data, not evidence of none. Float is small: 31.91M shares outstanding.
  • Analyst dispersion is wide relative to the price — a $12.00 low and a $24.00 high in the six-analyst aggregate — which is what thin coverage of a levered turnaround looks like.

Catalyst Calendar (next 30 days)

  • 2026-08-22 → 2026-09-21: no company-scheduled event identified. No earnings date, no capital-markets day, no regulatory deadline is on the calendar inside the window.
  • ~2026-10-28 (est.): Q3 2026 results. Date unconfirmed; Q3 2025 was reported 2025-10-29 and Q3 2024 on 2024-11-07. This is the first hard test of the 8–10% constant-currency guide and of whether adjusted EBITDA tracks the $25M low end or the $35M high end, plus the next disclosure of cash against the $517.8M borrowing balance.
  • 2028-09-14: maturity of the 9.25% Convertible Senior PIK Notes — a standing structural date, not a near-term event, but the reason any interim financing announcement would be material.

What Would Change Our Mind

The structure that matters is the August shelf: the $13.035 and $13.150 closes on 2026-08-11 and 2026-08-12 are the only floor the post-guidance advance has produced. A weekly close below $13.00 removes it and puts the whole 2026-07-22 gap back in play. Below $11.00 the entire advance that followed the guidance raise is ceded.

On the fundamental side, a Q3 2026 print (~2026-10-28, est.) that walks FY constant-currency growth back toward the old 3–5% band, or that narrows adjusted EBITDA below the $25M low end, breaks the reason the multiple moved. A Form 6-K announcing an equity offering, an ATM programme or an equity-linked refinancing would resolve the leverage question in the direction the equity cannot absorb. The passage of the 30-day window with no company news and no new high would confirm the maturing label rather than refute it; a flip to saturated would require mainstream coverage arriving into a price that has stopped responding.

Correlation Notes

  • Reports in USD with Europe & International as the largest growth contributor (+21.0% reported vs +18.0% cc in Q2 2026), so EUR/SEK–USD moves show up directly in reported revenue and in whether the $908.799M–$925.629M dollar guide is reachable.
  • Capital stack is multi-currency: SEK 1,700M Nordic bonds and a SEK 750M super senior RCF alongside the USD convertibles, so Nordic credit conditions and the dollar both feed the refinancing question.
  • Sits in the levered small-cap consumer complex rather than with staples majors: 31.91M shares outstanding and $462.73M of market value against $517.8M of borrowings means the equity behaves like the residual claim it is, with high beta to risk appetite and to headlines on plant-based peers.
  • Greater China (+11.6% reported, +5.6% cc in Q2 2026) carries tariff and geopolitical sensitivity that management flagged on the 2026-07-22 call.

Notes

  • Foreign private issuer: reports on Form 6-K and 20-F, not 10-Q/10-K.
  • Reports in USD while the largest growth region is European, so reported and constant-currency growth diverge every quarter.
  • 9.25% Convertible Senior PIK Notes due 2028-09-14 accrete interest rather than pay cash, so principal compounds absent repurchase.
  • Capital stack is multi-currency: SEK 1,700M Nordic bonds and a SEK 750M super senior RCF alongside the USD convertibles.
  • Sell-side coverage is thin and aggregator target sets disagree: a one-analyst $14.00 alongside a six-analyst average of $17.25 in August 2026.
  • 31.91M shares outstanding gives a small float; single-print moves and index/screen flows can dominate short-run price action.

Related · shared themes

HUM

Humana Inc.

Margin-over-volume Medicare Advantage reset reclaimed its trend: the 2026-08-24 close of $386.61 is 2.0% above the prior session and back clear of the last 50-day value observed ($378.33, 2026-08-12), with RSI(14) at 64.6 from 52.5. Revision flow idle since Bernstein's 08-14 Buy/$425, and the 2027 number now has a venue — a 2026-12-10 investor update — past both the 09-08/10 conference window and the 11-06 print. The narrative is maturing.

MEDIUM

RXO

RXO, Inc.

Freight-cycle recovery intact; sell-side has fully caught up into a $20–35 battleground — bears $20 (Goldman 07-16, Susquehanna 07-14), bulls $30–35 (BMO $35 initiation 07-14, Stifel/Truist/Citi $30). Narrative matured from mispriced to consensus; the ~2026-08-05 Q2 print (adj EBITDA guide $27–37M vs $6M Q1) is the binary the whole re-rate discounts.

MEDIUM

CNC

Centene Corporation

Margin-repair guide raise of 2026-07-28 stays fully priced: the 2026-08-24 close of $65.65 is 2.7% under the 2026-08-14 close of $67.47 and 4.5% below the $68.72 52-week high, with no analyst target moved since Argus on 2026-08-11. maturing; the next company-controlled datapoint is Q3, now calendared 2026-10-27.

LOW

HNGE

Hinge Health, Inc.

Digital-MSK profitability re-rate broke out in May and was pushed into open price discovery by the 2026-06-09 mid-quarter raise (Q2 to $200–202M, +45%; FY26 to $818–824M). But nine sell-side target hikes in two weeks plus accelerating insider selling mark a late, distribution-prone phase, with no company catalyst until the ~2026-08-04 Q2 print.

LOW

See also · stocks to watch